CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: Medical Devices (6162)
The company's primary goals are to eliminate unnecessary breast surgeries, find the breast cancers that are often missed, facilitate the therapy delivery process, and save the company's healthcare system $2.3 billion annually. n
Company (Alive / Active)
3371 Melendy Drive
San Carlos, 94070
California, United States
| Total Funding | Date of Last Funding | |
|---|---|---|
| Bioluminate | $0M | Feb 3, 2020 |
| See all 13 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Company | Status | Description | Investors |
|---|---|---|---|
| Irvine, California, United States | Acquired | SenoRx develops surgical products for breast cancer. | Login to see details |
| Rockville, Maryland, United States | Alive / Active | 20/20 GeneSystems has developed, validated, and undergone clinical testing of a blood test for the early detection of lung cancer. The test measures a panel of tumor biomarkers and utilizes a proprietary algorithm to combine the biomarker values to generate a unitary risk score. | Login to see details |
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Multisensor probe for tissue identification | Aug 22, 2008 | May 17, 2011 | Patent |
